Market OpportunityThe initial creto label and guidelines inclusion would encompass approximately 25,000 patients, offering a multi-billion-dollar opportunity available to CGON even when accounting for competitors.
Market PenetrationCGON's cretostimogene (creto, oncolytic virus) is likely to be rapidly adopted and could penetrate as much as 50% of the BCG-unresponsive market.
Regulatory ProgressThe regulatory work at CGON is progressing well as management expressed a high level of confidence.